XASX
FPH
Market cap14bUSD
Sep 17, Last price
35.55AUD
1D
-0.03%
1Q
12.75%
Jan 2017
334.07%
IPO
1,362.96%
Name
Fisher & Paykel Healthcare Corporation Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Fisher & Paykel Healthcare Corporation Limited, operating with its various subsidiaries, is a global innovator in medical device technology. The company specializes in the design, production, and worldwide distribution of sophisticated products and systems. These solutions primarily cater to acute and chronic respiratory care, support during surgical procedures, and the treatment of obstructive sleep apnea (OSA) in both clinical settings and home environments. Their product lineup includes notable items such as the Airvo 2, a humidified nasal high flow system; Optiflow, designed for nasal high flow therapy; and the F&P 850 System, which offers both non-invasive and invasive ventilation capabilities. For infant care, the company supplies respiratory products used in resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy. Hospital-grade offerings comprise humidification devices, breathing circuits, chambers, diverse masks, nasal cannulas, surgical accessories, and various interfaces. For homecare users, Fisher & Paykel provides masks, CPAP devices, data management software, humidifiers, and complementary accessories. Established in 1934, the company maintains its headquarters in Auckland, New Zealand.
Key people
Lyndal Jane York
Chief Financial Officer · since 2019
Paul Nigel Shearer
Senior Vice President - Sales and Marketing · since 2001
Marcus Driller
Vice President - Corporate · since 2019
Winston Fong
Vice President - Surgical Technologies · since 2017
Nicholas Fourie
Vice President � Information & Communication Technology · since 2017
Debra Lumsden
Vice President of Human Resources and Private Officer · since 2016
Brian Schultz
Vice President - Quality & Regulatory · since 2015
Andrew Robert Donald Somervell
Vice President - Products & Technology · since 2016
Lewis George Gradon
Chief Executive Officer, Managing Director, Director · since 2016
Jonti Rhodes
General Manager - Supply Chain · since 2015
Non-Executive Director · since 2016
Non-Executive Independent Director · since 2017
Non-Executive Independent Director · since 2014
Arthur James Morris
Non-Executive Independent Director · since 2008
Non-Executive Independent Director · since 2014
Non-Executive Independent Director · since 2015
Valuation
Title NZD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||